INITIATION OF CELL INFECTION WITH EPSTEIN-BARR VIRUS
INITIATION OF CELL INFECTION WITH EPSTEIN-BARR VIRUS
批准号:
2633442
负责人:
Lindsey M. Hutt-Fletcher
金额:
$20.81万
依托单位国家:
美国
项目类别:
财政年份:
1984
资助国家:
美国
项目状态:
已结题
起止时间:
1984-01-01 至 1999-12-31
关键词:
B lymphocyte Epstein Barr virus SCID mouse epithelium gene deletion mutation hematopoietic tissue transplantation human subject human tissue laboratory rabbit latent virus infection membrane proteins point mutation tissue /cell culture transfection virus envelope virus infection mechanism virus protein virus receptors virus replication
中文摘要
EB病毒(EBV)是一种人类疱疹病毒,其建立慢性疱疹病毒感染。
携带者几乎占全世界人口的100%。
它作为一种与传染性疾病相关的病原体具有相当重要的意义。
单核细胞增多症,口腔毛状白斑,伯基特淋巴瘤,免疫母细胞
免疫抑制性淋巴瘤,鼻咽癌,T细胞
恶性肿瘤和霍奇金病。 目前的发病机制模型
表明EB病毒在上皮组织中高效复制
在口咽部并在B淋巴细胞中建立潜伏期。病毒然后贩运
当它进入人体并周期性地脱落时,
感染者的唾液中。这项工作的长期目标是
了解EBV感染两种靶细胞的第一步,
这对病毒在宿主内和宿主之间的传播至关重要。的
该应用程序的直接目标是使用最近开发的
获得EBV突变体的技术,以研究已知或
在这个过程中的推定EBV包膜蛋白。突变的表型
将在体外原代B淋巴细胞和SV 40中检查病毒
已用所述B细胞转染的转化上皮细胞系
EB病毒受体。 将在体内检查突变病毒的表型
在CB。17只scid/scid免疫缺陷小鼠移植人
淋巴上皮组织有三个具体目标。一是
检测缺失gp 85复合物中蛋白质表达的影响
病毒穿透细胞的能力。其他点突变
将评价gp 85对复合物完整性的影响
使用分离表达的重组蛋白;那些不
干扰复合物形成将被构建到病毒中,
功能分析第二个目的是检查病毒的表型
gp 110的表达缺失,其是HSV-gB的EBV同源物。第三
目的是确定是否有四个剩余的潜在病毒粒子
膜蛋白是病毒复制所必需的,
每个人的位置证明是这样的。
英文摘要
Epstein-Barr virus (EBV) is a human herpesvirus that establishes a chronic
carrier state in almost one hundred per cent of the population world-wide.
It has considerable importance as a pathogen associated with infectious
mononucleosis, oral hairy leukoplakia, Burkitt's lymphoma, immunoblastic
lymphomas of the immunosuppressed, nasopharyngeal carcinoma, T cell
malignancy and Hodgkin's disease. A current model of pathogenesis
suggests that EBV replicates productively in epithelial tissue of the
oropharynx and establishes latency in B lymphocytes. Virus then trafficks
between the two cell types as it enters the body and is periodically shed
in saliva of infected individuals. The long term objective of this work is
to understand the first steps in infection of both target cells of EBV
which are critical to spread of virus within and between hosts. The
immediate goals of this application are to use recently developed
techniques for deriving EBV mutants to investigate the roles of known or
putative EBV envelope proteins in the process. The phenotypes of mutated
virus will be examined in vitro in primary B lymphocytes and in an SV40
transformed epithelial cell line that has been transfected with the B cell
receptor for EBV. Phenotypes of mutated viruses will be examined in vivo
in CB. 17 scid/scid immunodeficient mice engrafted with human
lymphoepithelial tissue. There are three specific aims. The first is to
examine the effects of deleting expression of proteins in the gp85 complex
on the ability of virus to penetrate cells. Additional point mutations in
gp85 will be evaluated for their effects on the integrity of the complex
using recombinant proteins expressed in isolation; those that do not
interfere with complex formation will then be built into virus for further
functional analyses. The second aim is to examine the phenotype of virus
deleted for expression of gp110, the EBV homologue of HSV-gB. The third
aim is to determine whether or not four remaining potential virion
membrane proteins are essential for virus replication, and to examine the
location of each that proves to be so.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Anitbody and saliva-mediated enhancement of epithelial cell infection by EBV
-
批准号:8103016
-
项目类别:
-
资助金额:$27.83万
-
财政年份:2007
-
负责人:Lindsey M. Hutt-Fletcher
-
依托单位:
Anitbody and saliva-mediated enhancement of epithelial cell infection by EBV
-
批准号:7487007
-
项目类别:
-
资助金额:$28.98万
-
财政年份:2007
-
负责人:Lindsey M. Hutt-Fletcher
-
依托单位:
Anitbody and saliva-mediated enhancement of epithelial cell infection by EBV
-
批准号:7886763
-
项目类别:
-
资助金额:$28.69万
-
财政年份:2007
-
负责人:Lindsey M. Hutt-Fletcher
-
依托单位:
Anitbody and saliva-mediated enhancement of epithelial cell infection by EBV
-
批准号:7655263
-
项目类别:
-
资助金额:$28.98万
-
财政年份:2007
-
负责人:Lindsey M. Hutt-Fletcher
-
依托单位:
Anitbody and saliva-mediated enhancement of epithelial cell infection by EBV
-
批准号:7450235
-
项目类别:
-
资助金额:$29.3万
-
财政年份:2007
-
负责人:Lindsey M. Hutt-Fletcher
-
依托单位:
EBV Entry and Spread in the Oral Cavity
-
批准号:6912111
-
项目类别:
-
资助金额:$36.25万
-
财政年份:2005
-
负责人:Lindsey M. Hutt-Fletcher
-
依托单位:
EBV Entry and Spread in the Oral Cavity
-
批准号:8510124
-
项目类别:
-
资助金额:$21.6万
-
财政年份:2005
-
负责人:Lindsey M. Hutt-Fletcher
-
依托单位:
Epstein-Barr virus glycoproteins and virus spread
-
批准号:7557821
-
项目类别:
-
资助金额:$30.35万
-
财政年份:2005
-
负责人:Lindsey M. Hutt-Fletcher
-
依托单位:
EBV Entry and Spread in the Oral Cavity
-
批准号:7871395
-
项目类别:
-
资助金额:$35.17万
-
财政年份:2005
-
负责人:Lindsey M. Hutt-Fletcher
-
依托单位:
Epstein-Barr virus glycoproteins and virus spread
-
批准号:6984796
-
项目类别:
-
资助金额:$31.86万
-
财政年份:2005
-
负责人:Lindsey M. Hutt-Fletcher
-
依托单位:
EBV Entry and Spread in the Oral Cavity
-
批准号:7163503
-
项目类别:
-
资助金额:$34.37万
-
财政年份:2005
-
负责人:Lindsey M. Hutt-Fletcher
-
依托单位:
EBV Entry and Spread in the Oral Cavity
-
批准号:8456193
-
项目类别:
-
资助金额:$58.31万
-
财政年份:2005
-
负责人:Lindsey M. Hutt-Fletcher
-
依托单位:
EBV Entry and Spread in the Oral Cavity
-
批准号:7336841
-
项目类别:
-
资助金额:$33.99万
-
财政年份:2005
-
负责人:Lindsey M. Hutt-Fletcher
-
依托单位:
EBV Entry and Spread in the Oral Cavity
-
批准号:8056814
-
项目类别:
-
资助金额:$34.12万
-
财政年份:2005
-
负责人:Lindsey M. Hutt-Fletcher
-
依托单位:
Epstein-Barr virus glycoproteins and virus spread
-
批准号:7162177
-
项目类别:
-
资助金额:$30.93万
-
财政年份:2005
-
负责人:Lindsey M. Hutt-Fletcher
-
依托单位:
EBV Entry and Spread in the Oral Cavity
-
批准号:7755639
-
项目类别:
-
资助金额:$35.53万
-
财政年份:2005
-
负责人:Lindsey M. Hutt-Fletcher
-
依托单位:
EBV Entry and Spread in the Oral Cavity
-
批准号:7007724
-
项目类别:
-
资助金额:$35.4万
-
财政年份:2005
-
负责人:Lindsey M. Hutt-Fletcher
-
依托单位:
EBV Entry and Spread in the Oral Cavity
-
批准号:8269075
-
项目类别:
-
资助金额:$34.82万
-
财政年份:2005
-
负责人:Lindsey M. Hutt-Fletcher
-
依托单位:
Epstein-Barr virus glycoproteins and virus spread
-
批准号:6875523
-
项目类别:
-
资助金额:$32.63万
-
财政年份:2005
-
负责人:Lindsey M. Hutt-Fletcher
-
依托单位:
Epstein-Barr virus glycoproteins and virus spread
-
批准号:7337643
-
项目类别:
-
资助金额:$30.35万
-
财政年份:2005
-
负责人:Lindsey M. Hutt-Fletcher
-
依托单位:
海外基金